Friday, 23 Aug 2019

You are here

ACP Supports Transparency of Health Care Costs

The American College of Physicians (ACP) is encouraged by the Trump administration’s executive order to improve transparency of health care costs. ACP firmly believes that increasing health care transparency is critical in providing quality, affordable, and accessible health care coverage to patients who need it the most.

In ACP’s position paper, “Improving Health Care Efficacy and Efficiency Through Increased Transparency,” ACP’s recommendations supported transparency of reliable and valid price information, expected out-of-pocket costs, and quality data that allows consumers, physicians, payers, and other stakeholders to compare and assess medical services and products in a meaningful way.

ACP believes that health care facilities should clearly communicate to a patient whether a physician or other provider is in-network or out-of-network and the estimated out-of-pocket payment responsibilities of the consumer. Furthermore, the executive order calls for expanding access to health care data, as well as regulatory steps to address surprise billing—positive steps forward in promoting transparency for patients. ACP also supports efforts to consolidate quality metrics across federal health care programs, a move that could help to reduce the administrative burdens for physicians.

As a physician, I’ve seen how important it is to protect patients from high, unexpected out-of-pocket costs. Health care expenses should never be used as the sole criterion for choosing a physician, other health care professional, or health care service. While ACP supports the concept of the executive order, it should be implemented in a way that does not impose impracticable or excessive administrative burdens on clinicians, practices, and health care facilities in disclosing price data to patients.

ACP is hopeful that the executive order will not only increase transparency in health care costs, but will help patients better access affordable, quality care by holding the U.S. health care system accountable. We look forward to reviewing the administration’s proposals as they are made available.

Statement attributable to:
Robert McLean, MD, FACP
President, American College of Physicians

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

RheumNow Podcast – Upadacitinib FDA Approved for RA (8.23.19)

Dr. Jack Cush reports on the news and journal reports from the past week on RheumNow.com, including: how your genetics may shape your microbiome; GERD as a risk factor for TMJ?; how can MDA-5+ dermatomyositis be any worse; new drug happenings; StillsNow.com; and more.

RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)

Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.

RheumNow Podcast – Tricked Up Lupus Criteria (8.9.19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including new SLE criteria, ULT in gout and MSU reductions, IVIG in ANCA vasculitis and non-TNF biologics outperform the TNF inhibitors.

EULAR Recommendations on Large Vessel Vasculitis

Th European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) was originally published in 2009. Since then there have been new randomised clinical trials and cohort analyses leading to an update the original recommendations.

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com: MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.